Decoding STK11 in Lung Cancer Therapy

Explore the critical role of biomarker testing in lung cancer treatment with Dr. Salman Punekar, Medical Oncologist at NYU Langone Health. Specializing in early-phase clinical development, Dr. Punekar explains the function of the biomarker STK11, a newer discovery shaping approaches to non-small cell lung cancer therapies. 

Guests

Salman R. Punekar, MD, Assistant Professor of Medicine of Medical Oncology at NYU Langone Health. Specialization in early-phase clinical development and translational research.

Stephanie Williams, Lung Cancer survivor and clinical trial participant

Show Notes | Transcript | Watch Video

Unlocking Treatment Pathways for Lung Cancer

Highlighting the crucial role of biomarker testing in lung cancer, take an in-depth look at the function of STK11 as a tumor suppressor gene and its impact when mutated. Learn more about the latest research on the STK11 biomarker's influence on treatment strategies for non-small cell lung cancer from Dr. Salman Punekar. Dr. Punekar explains the function of STK11 as a tumor suppressor gene and its implications when mutated, affecting the efficacy of therapies like immunotherapy. STK11 is believed to negatively influence response to immune checkpoint inhibitors (ICIs) in non–small-cell lung cancer (NSCLC).

Then hear from Stephanie Williams, a lung cancer patient who underscores the life-changing impact of clinical trials, which informed her treatment and emphasized the importance of biomarker discovery. She shares why she advocates for patient education, the pursuit of clinical trials, and the need for ongoing research to improve lung cancer care.